42 citations
,
January 1998 in “BioDrugs” Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.
1 citations
,
September 2001 in “PubMed” Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
May 2015 in “Journal of The American Academy of Dermatology” Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.
22 citations
,
October 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Combining isotretinoin and dapsone effectively treated a challenging scalp condition.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
14 citations
,
June 2013 in “Joint Bone Spine” ACTH may be an effective first-line treatment for acute calcium pyrophosphate crystal arthritis.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
9 citations
,
November 2017 in “International Journal of Nanomedicine” Tiny particles called anionic squarticles can effectively remove a common antidepressant from the body after an overdose.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
41 citations
,
March 2017 in “PLoS neglected tropical diseases” Isotretinoin shows promise as a treatment for Chagas disease by effectively inhibiting key transporters in the parasite.
October 2025 in “Indian Dermatology Online Journal” 2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.
11 citations
,
April 1997 in “International Journal of Dermatology” Using tretinoin with triamcinolone acetonide helps treat alopecia areata.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
April 2024 in “Skin research and technology” Minoxidil with triamcinolone acetonide is more effective for mild alopecia areata when injected with microneedles than when applied topically.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
1 citations
,
January 2021 in “Dermatologic Therapy” Candida antigen is an effective and promising treatment for alopecia areata.
Baricitinib is more effective than methotrexate for severe alopecia areata.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.